Elabscience

Recombinant Human SFTPD/SP-D Protein (His Tag)

Product Code:
 
PKSH031293
Product Group:
 
Recombinant Proteins
Supplier:
 
Elabscience
Host Type:
 
Human
Regulatory Status:
 
RUO
Shipping:
 
This product is provided as lyophilized powder which is shipped with ice packs.
Storage:
 
Generally lyophilized proteins are stable for up to 12 months when stored at -20 to -80°C. Reconstituted protein solution can be stored at 4-8°C for 2-7 days. Aliquots of reconstituted samples are stable at < -20°C for 3 months.
1 / 1

No additional charges, what you see is what you pay! *

CodeSizePrice
PKSH031293-100ug100ug£664.00
Quantity:
Prices exclude any Taxes / VAT
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: China.
Typical lead time: 14-21 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • Show All

Further Information

Abbreviation:
SFTPD;SP-D
Accession:
NP_003010.4
Background:
Surfactant pulmonary-associated protein D, also known as SFTPD and SP-D, is a member of the collectin family of C-type lectins that is synthesized in many tissues including respiratory epithelial cells in the lung, and contains one C-type lectin domain and one collagen-like domain. The polymorphic variation in the N-terminal domain of the SP-D molecule influences oligomerization, function, and the concentration of the molecule in serum. SFTPD is produced primarily by alveolar type II cells and nonciliated bronchiolar cells in the lung and is constitutively secreted into the alveoli where it influences surfactant homeostasis, effector cell functions, and host defense. It is upregulated in a variety of inflammatory and infectious conditions including Pneumocystis pneumonia and asthma. SFTPD is humoral molecules of the innate immune system, and is considered a functional candidate in chronic periodontitis. Besides it is involved in the development of acute and chronic inflammation of the lung. Several human lung diseases are characterized by decreased levels of bronchoalveolar SFTPD. Thus, recombinant SFTPD has been proposed as a therapeutical option for cystic fibrosis, neonatal lung disease and smoking-induced emphysema. Furthermore, SFTPD serum levels can be used as disease activity markers for interstitial lung diseases.
Calculated MW:
37 kDa
Endotoxin:
< 1.0 EU per ug of the protein as determined by the LAL method.
Expression Host:
HEK293 Cells
Formulation:
Lyophilized from sterile PBS, pH 7.4
Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization.
Please refer to the specific buffer information in the printed manual.
Fusion tag:
C-His
ObservedMW:
47 kDa
Purity:
> 90 % as determined by reducing SDS-PAGE.
Sequence:
Met 1-Phe 375
Target Synonym:
Pulmonary Surfactant-Associated Protein D;PSP-D;SP-D;Collectin-7;Lung Surfactant Protein D;SFTPD;COLEC7;PSPD;SFTP4;COLEC7;SFTP4

Documents